VivaVision Biotech Strengthens Advisory Board with Expert
Recently, VivaVision Biotech Co., Ltd. (VivaVision) proudly announced the addition of Dr. Quan Dong Nguyen, a globally recognized figure in the field of ophthalmology, to its Scientific Advisory Board. This strategic appointment marks a significant step forward for the company as it furthers its commitment to innovative eye care solutions.
Meet Dr. Quan Dong Nguyen
Dr. Quan Dong Nguyen is currently affiliated with the Byers Eye Institute at Stanford University, where he serves as a professor of ophthalmology and has further appointments in medicine and pediatrics. His research primarily revolves around clinical trials for macular edema, neovascular age-related macular degeneration (AMD), and various ocular inflammatory diseases. Having pioneered evaluations of drugs like aflibercept and ranibizumab, Dr. Nguyen's contributions are foundational in establishing effective treatment protocols for retinal problems.
Impact on VivaVision's Projects
Dr. Nguyen's expertise is expected to significantly enhance VivaVision's research and development initiatives. He expressed enthusiasm about joining the team and highlighted the potential of VivaVision's dual JAK1/TYK2 inhibitors, VVN461 and VVN481, developed for treating ocular inflammatory conditions. These innovative therapies aim to provide patients with safer alternatives to current corticosteroid treatments.
Comments from Leadership
Wang Shen, the Founder and CEO of VivaVision Biotech, expressed honor at having Dr. Nguyen join the advisory board. He emphasized that Dr. Nguyen’s extensive knowledge in managing conditions such as diabetic macular edema and inflammatory diseases will be invaluable as VivaVision continues to expand its research endeavors.
About VivaVision
Established in 2016, VivaVision Biotech focuses on pioneering clinical therapies for ocular diseases. With a commitment to addressing unmet medical needs, the company is advancing leading-edge treatments, including:
Innovative Pipeline Developments
1. VVN461: A dual JAK1/TYK2 immunomodulator designed to manage post-operative inflammation and non-infectious anterior uveitis.
2. VVN001: An investigational remedy for dry eye disease.
3. VVN1901: Targeted treatment for neurotrophic keratitis.
4. VVN481: A non-steroidal treatment for posterior uveitis and related inflammatory conditions.
In addition, VivaVision is dedicated to discovering groundbreaking therapies that tackle both anterior and posterior ocular diseases, effectively addressing the challenges faced by patients worldwide.
Frequently Asked Questions
What is the significance of Dr. Quan Dong Nguyen's appointment?
Dr. Nguyen's experience in clinical trials and ocular diseases strengthens VivaVision's advisory board, enhancing its research capabilities.
What are VVN461 and VVN481?
These are dual JAK1/TYK2 inhibitors aimed at treating ocular inflammatory diseases and offer new options for patients.
When was VivaVision Biotech founded?
VivaVision Biotech was founded in 2016 with a focus on developing innovative therapies for eye diseases.
What conditions does VivaVision's pipeline aim to treat?
VivaVision's pipeline focuses on various ocular diseases, including dry eye disease, inflammation, and retinal disorders.
How does VivaVision approach research and development?
The company emphasizes innovative strategies to address unmet patient needs in ocular health through advanced therapies.